Compare WMB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WMB | VRTX |
|---|---|---|
| Founded | 1908 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | EDP Services |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5B | 115.7B |
| IPO Year | 2002 | 2006 |
| Metric | WMB | VRTX |
|---|---|---|
| Price | $71.57 | $442.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 29 |
| Target Price | $76.41 | ★ $539.69 |
| AVG Volume (30 Days) | ★ 5.5M | 1.2M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | 17.58 | ★ 836.54 |
| EPS | 2.14 | ★ 15.32 |
| Revenue | ★ $11,950,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.85 | $10.81 |
| Revenue Next Year | $9.86 | $10.41 |
| P/E Ratio | $33.44 | ★ $28.74 |
| Revenue Growth | 13.78 | ★ 46.20 |
| 52 Week Low | $55.56 | $362.50 |
| 52 Week High | $76.87 | $510.77 |
| Indicator | WMB | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 46.35 |
| Support Level | $57.04 | $427.52 |
| Resistance Level | $76.12 | $467.86 |
| Average True Range (ATR) | 1.77 | 10.92 |
| MACD | -0.28 | 0.45 |
| Stochastic Oscillator | 30.65 | 56.89 |
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.